complessi, o sottoposti precedentemente a numerosi interventi.
Nonostante l’invasività dell’intervento, questo studio ha dimostrato che nei casi di glaucoma refrattario, un reimpianto della valvola di Ahmed può essere considerato una valida scelta, sia in termini di controllo della pressione intraoculare sia nella riduzione del numero di farmaci assunti dai pazienti mostrando una stabilità dell'acuità visiva.
Il principale limite di questo studio può essere considerato il tempo di follow-up; infatti nonostante nelle visite successive i 30 mesi abbiamo ottenuto un successo statisticamente significativo (P-value <0,001) il campione è andato riducendosi. Ciò potrebbe rappresentare un limite per la significatività dei dati a lungo termine.
5 Bibliografia
1. Casson RJ, Chidlow G., Wood JP, Crowston JG and Goldberg I. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol 2012 May-Jun; 40 (4): 341– 349.
2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090.
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7.
4. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109:1090-5.
5. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open angle glaucoma in Australia–The Blue Mountains Eye Study. Ophthalmology. 1996;103:1661-9.
6. Ronan Conlon, MD, Hady Saheb, MD, MPH, FRCSC, Iqbal Ike K. Ahmed, MD, FRCSC. Glaucoma treatment trends: a review. Can J Ophthalmol 2016.
7. Coffey M, Reidy A, Wormald R, Wu XX, Wright L, Courtney P. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol 1993; 77:17-21.
8. Dielemans I, Vingerling JR, Wolfs RCW, Hofman A, Grobee DE, de Jong PTVM. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. Ophthalmology 1994; 101: 1851-55.
9. Tielsch JM, Sommer A, Katz J, Quigley HA, Royall RM, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. JAMA 1990; 266: 369-74.
10. Graham SL, Drance SM, Wijsman K. Ambulatory blood pressure monitoring in glaucoma. The nocturnal dip. Ophthalmology 1995; 102: 61-69.
11. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol 1999; 43: S10-S16.
12. Varma R, Ying-Lai M, Francis BA, Nguyen BBT, Deneen J, Wilson R, et al. Prevalence of open-angle glaucoma and ocular hypertension in latinos. The Los Angeles Latino Eye Study. Ophthalmology 2004; 111: 1439-48.
13. Dielemans I, Vingerling JR, Wolfs RCW, Hofman A, Grobee DE, de Jong PTVM. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. Ophthalmology 1994; 101: 1851-55.
14. Heijl A, Leske MC, Bengtsson B for the EMGT group. Reduction of intraocular pressure and glaucoma progression. Results of the Early Manifest Glaucoma Trial. Arch
16. Jack J. Kanski. Oftalmologia clinica. Sesta edizione, 2008. 17. Stefano Gandolfi. Il Glaucoma. 2005.
18. Lutjen-Drecoll E, Rohen JW: Morphology of aqueous outflow pathways in normal and glaucomatous eyes. In Ritch R, Shields MB, Krupin T Editors. The Glaucomas. St Louis, Mosby, 1996; 89-124.
19. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Survey of ophthalmology 199); 39(1): 23-)2.
20. Ritch R, Schlotzer-Schrehardt U, Konstas AG. Why is glaucoma associated with exfoliation syndrome? Prog Retin Eye Res 2003; 22(3):253-75.
21. Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma--a major review. Clinical & experimental ophthalmology 2008; 36(9): 868- 82.
22. Caprioli J. Clinical evaluation of the optic nerve in glaucoma. Trans Arn Ophthalmol Soc. 199); 92: 589-6)1.
23. Shaffer RN. Symposium: Primary glaucomas III. Gonioscopy, uphthalmoscopy and peri- metry. Trans Am Acad Ophthalmol Otolaryngol 1960;6):112-27.
24. Goldmann, H. and Schmidt, T. (1961) Weiterer Beitrag zur Applanations tonometrie. Ophthalmologica 141,441-456.
25. Sródka W. Goldmann applanation tonometry - not as good as gold. Acta Bioeng Biomech. 2010; 12(2): 39-47.
26. Boland MV, Ervin AM, FriedmanDS, et al. Comparative effectiveness of treatments for open angle glaucoma: a systematic review for the US Preventive Services Task Force. Ann Intern Med.2013; 158: 271-9.
27. Neufeld AH, Page ED. In vitro determination of the ability of drugs to bind to adrenergic receptors. Invest Ophth Vis Sci 1977; 16(12): 1118-24.
28. Kaufman PL. Physiologic mechanism underlying the medical therapy of glaucoma. Atti Glaucoma Symposium, ICO XXVI, Singapore 1990 16-17 Marzo.
29. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005; 62: 691-9.
30. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Increased matrix metalloproteinases 1, 2, and 3 in monkey uveoscleral outflow pathway after topic prostaglandin F (2alpha)-isopropyl ester treatment. Arch Ophthalmol. 2001; 119: 1165- 70.
31. Richter M, Kraus AH, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest ophthalmol Vis Sci 2003; 44: 4419- 4426.
32. Sears ML. The mechanism of action of adrenergic drugs in glaucoma. Inv Ophthalmol. Vis Sci. 1966; 5: 115-21.
33. Maren TH. The rates of movement of Na, Cl and HCO3 from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma, Invest Ophthalmol 1971; 85:1.
34. http://www.oculistaitaliano.it/articoli/chirurgia-del-glaucoma-oggi-e-domani; M.Nardi. 35. European Glaucoma Society (EGS). Terminology and guidelines for glaucoma. Il ed
Dogma, Savona (Italy) 2003; 3.6.
36. Stendman's Medicai Dictionary, 25th ed. Baltimore, Williams e Wilkins 1989.
37. Ayyala RS, Zurakowski D, Smith JA, et al. A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma. Ophthalmology. 1998;105(10):1968-1976. 38. Goleman AL, Smyth RJ, Wilson MR, Tarn M. Initial clinical experience with the
Ahmed Glaucoma Valve implant in pediatrie patients. Arch Ophthalmol. 1997;115(2):186-191.
39. Gil-Carrasco F, Salinas- VanOrman E, Recillas-Gispert C, Paczka JA, Gilbert ME, Arellanes-Garcia L. Ahmed valve implant far uncontrolled uveitic glaucoma. Ocul Immunol Inflamm. 1998;6(1) :27-37.
40. Huang MG, Netland PA, Coleman AL, Siegner SW, Master MR, Hill RA. Intermediate-term clinical experience with the Ahmed Glaucoma Valve implant. AmJ Ophthalmol. 1999;127(1):27-S3.
41. Topouzis F, Coleman AL, Choplin N, et al. Follow-up of the originai cohort with theAhmed glaucoma valve implant. Am J■ Ophthalmol. 1999;128(2):198-204. 42. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus
Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789-803 e782.
43. Gedde SJ, Singh K, Schiffman JC, Feuer WJ, Tube Versus Trabeculectomy Study G.Tube Versus Trabeculectomy Study: interpretation of results and application to clinical practice. Curr Opin Ophthalmol. 2012;23(2):118-126.
44. Leen MM, Witkop GS, George DP. Anatomie considerations in the implantation of the Ahmed glaucoma valve. Ardi Ophthalmol 1996; 114:223-4.
45. Ventura MP, Vianna RN, Souza Filho JP, et al. Acquired Brown's syndrome secondary to Ahmed valve implant for neovascular glaucoma. Eye 2005;19:230-2.
46. Hill RA, Pirouzian A, Liaw L. Pathophysiology of and prophylaxis against late Ahmed glaucoma valve occlusion. Am J Ophthalmol 2000;129:608-12.
2008;17:584-90.
49. Scott GR, Weizer JS, Moroi SE, et al. Can topical ketorolac 0.5% improve the function of Ahmed glaucoma drainage devices Ophthalmic Surg Lasers Imaging 2011;42:190- 5.
50. Yuen D, Buys Y, Jin YP, et al. Gorticasteroids versus NSAIDs on intraocular pressure and the hypertensive phase after Ahmed glaucoma valve surgery. J Glaucoma 2011;20:439-44.
51. Park HY, Lee NY, Park CK. Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant. J Glaucoma 2009;18:44-8.
52. Tsai JC, Johnson CC, Kammer JA, et al. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma. II: Longer term outcomes from a single surgeon. Ophthalmology 2006;113:913-17.
53. Mills RP, Reynolds A, Emond MJ, Barlow WE, Leen MM. Long-term survival of Molteno glaucoma drainage devices. Ophthalmology. 1996; 103(2): 299-305.
54. Molteno ACB, Suter AJ, Fenwick M, et al. Otago Glaucoma Surgery Outcome Study: cytology and immunohistochemical staining of bleb capsules around Molteno implants. Invest Ophthalmol Vis Sci 2006;47:1975–81.
55. Molteno ACB, Fucik M, Dempster AG, et al. Otago Glaucoma Surgery Outcome Study. Factors controlling capsule fibrosis around Molteno implants with histopathological correlation. Ophthalmology 2003;110:2198–206.
56. Shaarawy M.T, Sherwood M.B, Hitchings R.A, Crowston J.G, Glaucoma, second edition 2015.
57. Roy S, Ravinet E, Mermoud A. Baerveldt implant in refractory glaucoma: long-term resultsand factors mfluencing outcome. Ini Ophthalmol. 2001; 24(2): 93-100.
58. H. Weve, Clinische lessen.Nederlands Tijdschrift voor Geneeskunde, vol. 76, pp. 5335-5336,1932.
59. A.De Roetth Jr, Cryosurgery for treatment of glaucoma. Transactions of the American Ophthalmological Society, vol. 63, no. 3, pp. 189-204,1965.
60. A.R.Bellows and W.M. Grant, Cyclocryotherapy of chronic open angle glaucoma in aphakic eye. American Journal of Ophthalmology, vol 85, no. 5 pt 1, pp. 615 621, 1978.
61. R.G. Gieser and D.K. Gieser, Treatment of intravitreal ciliary body neovascularization, Ophthalmic Surgery, vol 15, no. 6,pp. 508-509,1984.
62. M.B. Shields, D. B. Chandler, D. Hickingbotharn, and G.K. Klintworth, Intraocular cyclophotocoagulation. Histopathologic evaluation in primates. Archives of Ophthalmology,vol.103, no. 11, pp. 1731-1735,1985.
63. A. L. Coleman, H. D. Jampel, J. C. Javitt, A. E. Brown, and H. A. Quigley, “Transscleral cyclophotocoagulation of human autopsy and monkey eyes,”
Ophthalmic Surgery, vol. 22, no. 11, pp. 638–643, 1991.
64. L. F. Rosenberg, J. M. Ruderman, and R. B. O’Grady, “Trans- scleral cyclophotocoagulation. Localization of ciliary process destruction (abstract),” Investigative Ophthalmology & Visual Science, vol. 30, Supplement, pp. 353–356, 1989.
65. M. Uram, “Ophthalmic laser microendoscope ciliary process ablation in the management of neovascular glaucoma,” Ophthalmology, vol. 99, no. 12, pp. 1823– 1828, 1992.
66. D. J. Coleman, F. L. Lizzi, J. Driller et al., “Therapeutic ultra- sound in the treatment of glaucoma: I. experimental model,” Ophthalmology, vol. 92, no. 3, pp. 339–346, 1985. 67. D. J. Coleman, F. L. Lizzi, J. Driller et al., “Therapeutic ultra- sound in the treatment of
glaucoma: II. Clinical applications,” Ophthalmology, vol. 92, no. 3, pp. 347–353, 1985. 68. F. Aptel, T. Charrel, X. Palazzi, J. Y. Chapelon, P. Denis, and C. Lafon, “Histologic
effects of a new device for high-intensity focused ultrasound cyclocoagulation,” Inves- tigative Ophthalmology & Visual Science, vol. 51, no. 10, pp. 5092–5098, 2010. 69. R. Mastropasqua,V. Fasanella, A. Mastropasqua, M.Ciancaglini, L. Agnifili, High-
Intensity Focused Ultrasound Circular Cyclocoagulation in Glaucoma: A step Forward for Cyclodestruction?. Journal of Ophthalmology vol 2017.
70. P. Denis, F. Aptel, J.F. Rouland, J.P. Nordmann, Y. Lachkar, J.P. Renard, E. Sellem, C. Baudouin, and A. Bron, Cyclocoagulation of the Ciliary Bodies by High-Intensity Focused Ultrasound: a 12-Month Multicenter Study. IOVS ARVO journal, vol. 56. no. 2, February 2015.
71. Ishida K, Netland PA, Costa VP, Shirmoa L, Khan B, Ahmed II (2006) Comparison of polypropylene and silicone Ahmed glaucoma valves. Ophahtlrnology 118:1320- 1326.
72. Christakis PG, Kalenak JW, Tsai JC, et al. The Ahmed Versus Baerveldt Study: Five Year Treatment Outcomes. Ophthalmology. 2016; 12S(10):2093-2102.
73. Budenz DL, Barton K, Gedde SJ, et al. Five year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology 2015;122 (2): 308-316.
74. Burgoyne JK, WuDunn D, Lakhani V, Cantar LB (2000) Outcomes of sequential tube shunts in complicated glaucoma. Ophthalmology 107(2):309-314.
75. Anand A, Tello C, Sidoti PA, Pitch R, Liebmann JM (2010) Sequential glaucoma implants in refractory glaucom.a. Am, J Ophthalmol 149(1):95-101.
76. Hu WD, Master MR, Zheng CX, et al. . Outcomes of Sequential Glaucoma Drainage Implants in Refractory Glaucoma. J Glaucoma. 2016;25(4):e340-345.
78. Jimenez-Roman J, et al Jntraocular pressure control after the implantation of a second Ahmed glaucoma valve, Int Ophthamol (2015).
79. Smith M, Buys YM, Trope G.E. Second Ahmed valve insertion in the same eye. J Glaucoma 2009;18:336-340.
80. Nilforushan N., Yadgari M., Jazayeri A.A., Karimi N. Evaluation of success after second Ahmed glaucoma valve implantation, Indian J Ophthalmol. 2016 Mar; 64 (3):206-210.
81. Shah AA, WuDunn D, Cantar LB (2000) Shunt revision versus additional tube shunt implantation after failed tube shunt surgery in refractory glaucoma. Am J Ophthalmol 129(4):455-460 11.
82. Desai MA, Gedde SJ, Feuer WJ, Shi W, Chen PP, Parrish RK, 2nd. Practice preferences for glaucoma surgery: a survey of the American Glaucoma Society in 2008. Ophthalmic Surg Lasers Imaging. 2011;42(3):202-208. 9.
83. Ramulu PY, Corcoran KJ, Corcoran SL, Robin AL. Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004- Ophthalmology. 2007;114(12):2265-2270.